Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Squarepoint Ops LLC cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 89.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,004 shares of the company's stock after selling 51,329 shares during the quarter. Squarepoint Ops LLC's holdings in Tarsus Pharmaceuticals were worth $332,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Summit Investment Advisors Inc. grew its stake in shares of Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares during the period. Sherbrooke Park Advisers LLC grew its stake in shares of Tarsus Pharmaceuticals by 7.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock worth $364,000 after acquiring an additional 443 shares during the period. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $25,000. Bank of New York Mellon Corp grew its stake in shares of Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after acquiring an additional 498 shares during the period. Finally, Swiss National Bank grew its stake in shares of Tarsus Pharmaceuticals by 1.2% during the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after acquiring an additional 600 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS traded down $1.94 during trading hours on Tuesday, hitting $41.17. The company had a trading volume of 568,786 shares, compared to its average volume of 701,311. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The firm has a 50 day simple moving average of $45.89 and a 200 day simple moving average of $48.79. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -10.81 and a beta of 0.83.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Guggenheim increased their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Oppenheimer started coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target for the company. Finally, HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research note on Tuesday, May 27th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $66.67.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares in the company, valued at approximately $3,273,628.80. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now owns 58,057 shares of the company's stock, valued at $2,687,458.53. The trade was a 5.44% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,542 shares of company stock valued at $1,581,173. 8.97% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.